KN046 plus targeted pills for resistant MSI-H digestive cancers
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests two types of targeted therapy pills (Regorafenib or Apatinib) combined with a new immunotherapy drug (KN046). It is for people with MSI-H or dMMR digestive system cancers that have stopped responding to standard immunotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a digestive system cancer (like colorectal, stomach, or small intestine cancer) that is MSI-H or dMMR.
- Your cancer must have stopped responding to a prior PD-1 or PD-L1 immunotherapy treatment.
- You must be 18 years or older and in fairly good health (able to do daily activities with little to no help).
- You should not have taken Regorafenib or Apatinib combined with immunotherapy before.
- You must have tumor tissue available for testing, or be willing to provide a new biopsy.
- Your heart, liver, kidney, and blood function must be adequate based on blood tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs, KN 046 and regorafenib, in people with a type of advanced colorectal cancer that has not responded to previous treatments. The goal is to see if this combination can help shrink or control the tumor.
This Phase 2 trial tests KN035 in people with advanced or spread-out tumors that have specific genetic markers (MSI-H or dMMR). If you qualify, the study team will look at how well the drug works and how it affects side effects in that group.
This trial tests a combination of a targeted therapy pill (TKI) and an immunotherapy (PD-1 inhibitor) for people with advanced colorectal cancer that has stopped responding to standard treatments. It uses a blood test to tailor the treatment, aiming to be more effective with fewer side effects.
This trial tests a combination of a GSL synthesis inhibitor, an immunotherapy drug, and/or regorafenib in people with a specific type of colorectal cancer (pMMR/MSS) that has not responded to at least two prior treatments. The goal is to see if this new approach can help shrink or control the cancer.
This trial tests a new drug called JMKX005425 for people with advanced solid tumors that have a specific genetic feature called MSI-H or dMMR. If you have this feature and your cancer has not responded to other treatments, this study may offer a new option.
This early-phase study tests whether KC1036 can treat advanced digestive system cancers that have come back or spread after standard treatment. It may help people by shrinking tumors or slowing growth, and it will also check safety and side effects.
Hear when a new Digestive System Cancers trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.